Pioneering the development
of engineered IgM antibodies
IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 26, 2020
– Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in…
IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020
March 19, 2020
MOUNTAIN VIEW, Calif., March 19, 2020 – IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology…
IGM Biosciences to Present at Two Upcoming Investor Conferences
March 4, 2020
MOUNTAIN VIEW, Calif., March 04, 2020 — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company…
IGM Biosciences to Present at Two Upcoming Investor Conferences
February 6, 2020
MOUNTAIN VIEW, Calif., Feb. 06, 2020 – IGM Biosciences, Inc. (Nasdaq: IGMS), a global leader in…
IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis
January 7, 2020
Expert in the research and development of apoptotic pathways and antibody drug conjugates. MOUNTAIN VIEW,…